On January 8, 2014, GlaxoSmithKline plc and Theravance Inc. announced the launch of RELVAR® ELLIPTA® (fluticasone furoate/vilanterol) in the United Kingdom (UK), the first inhaled corticosteroid/long acting beta2-agonist (ICS/LABA) combination to provide continuous 24-hour efficacy for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in a practical once-daily dose.  Relvar is a combination of the inhaled corticosteroid (ICS), fluticasone furoate ‘FF', and the long-acting beta2-agonist (LABA), vilanterol ‘VI' (FF/VI) and is the first ICS/LABA to launch in the UK with both an asthma and COPD indication at the same time.  Two strengths of FF/VI have been approved for the treatment of asthma (92/22 mcg and 184/22 mcg) and one strength has been approved for COPD (92/22 mcg).  All strengths will be administered once daily using the Ellipta, a new dry powder inhaler (DPI).  FF/VI has been developed under the LABA collaboration agreement between Glaxo Group Limited and Theravance Inc.